Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Cash flow from operating activities:
Net loss	$ (5,836,592)	$ (6,640,301)
Adjustments to reconcile net loss to net cash used in operating activities:
Recognition of credit loss on notes receivable	787,524
Accrued interest revenue	(34,917)
Loss on equity method investment	439,637	1,606,294
Gain on revaluation of equity method investment	(6,164,260)
Depreciation and amortization	483,631	105,569
Vesting expense	2,004,366	800,322
Equity instruments issued for management and consulting		295,000
Amortization of debt discount	1,621,181
Gain on valuation of equity-linked instruments	(84,627)
Gain on revaluation of cash advances to Helomics	(1,222,244)
Debt extinguishment costs	204,750
Loss on fixed asset disposal	293
Changes in assets and liabilities:
Accounts receivable	68,252	(101,099)
Inventories	60,638	(13,110)
Prepaid expense and other assets	33,834	70,536
Accounts payable	942,183	268,637
Accrued expenses	751,975	(470,176)
Deferred revenue	7,573	8,643
Net cash used in operating activities	(5,936,803)	(4,069,685)
Cash flow from investing activities:
Redemption of certificates of deposit		244,971
Advance on notes receivable	(975,000)	(124,774)
Cash received from notes receivable	154,418
Cash received in Helomics Acquisition	248,102
Purchase of fixed assets	(855)	(169,983)
Acquisition of intangibles	(18,419)	(46,398)
Net cash used in investing activities:	(591,754)	(96,184)
Cash flow from financing activities:
Proceeds from debt issuance	2,250,000
Repayment of debt	(609,514)
Proceeds from exercise of warrants into common stock	5,970	650,062
Proceeds from issuance of Series E convertible preferred stock	2,338,840
Issuance of common stock	2,479,708	2,959,509
Net cash provided by financing activities	6,465,004	3,609,571
Net decrease in cash and cash equivalents	(63,553)	(556,298)
Cash at beginning of period	162,152	766,189
Cash at end of period	98,599	209,891
Non-cash transactions:
Bridge loan conversion into common stock	338,573
Forbearance settlement bridge loan	503,009
Value of warrants issued (iv)	47,078
Warrants issued pursuant to debt issuance	180,640
Consideration given for acquisition of Helomics	26,711,791	1,542,250
Shares issued into escrow for TumorGenesis		877,500
Bridge loan receivable		1,815,000
Conversion of preferred stock to common stock		$ 6,479